PFOS Disrupts Key Developmental Pathways during hiPSC Derived Cardiomyocyte Differentiation In Vitro
Researchers examined the effect of perfluorooctanesulfonic acid (PFOS) on cardiomyocyte differentiation by transcriptomics profiling of two different hiPSC lines to see if they exhibited a common pattern of disruption.
[Bellerophon Therapeutics, Inc.] Bellerophon Therapeutics, Inc. announced that the FDA has accepted the company’s proposal to reduce the study size for its ongoing registrational REBUILD Phase III trial of INOpulse® for the treatment of fibrotic interstitial lung disease.
[Nature Communications] Researchers determined transcriptional changes of idiopathic pulmonary fibrosis-airway basal cells and their potential profibrotic properties using a 3D culture system and novel mouse xenograft models.
[JCI Insight] Investigators found that growth factor–β1-mediated upregulation of UHRF1 repressed Beclin1 via promoter methylation induction which resulted in fibroblast activation and lung fibrosis both in vitro and in vivo.